1. Home
  2. ADPT vs EYE Comparison

ADPT vs EYE Comparison

Compare ADPT & EYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • EYE
  • Stock Information
  • Founded
  • ADPT 2009
  • EYE 1990
  • Country
  • ADPT United States
  • EYE United States
  • Employees
  • ADPT N/A
  • EYE N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • EYE Ophthalmic Goods
  • Sector
  • ADPT Health Care
  • EYE Health Care
  • Exchange
  • ADPT Nasdaq
  • EYE Nasdaq
  • Market Cap
  • ADPT 1.8B
  • EYE 1.9B
  • IPO Year
  • ADPT 2019
  • EYE 2017
  • Fundamental
  • Price
  • ADPT $12.85
  • EYE $23.48
  • Analyst Decision
  • ADPT Strong Buy
  • EYE Buy
  • Analyst Count
  • ADPT 8
  • EYE 9
  • Target Price
  • ADPT $12.38
  • EYE $21.78
  • AVG Volume (30 Days)
  • ADPT 1.8M
  • EYE 2.2M
  • Earning Date
  • ADPT 08-05-2025
  • EYE 08-06-2025
  • Dividend Yield
  • ADPT N/A
  • EYE N/A
  • EPS Growth
  • ADPT N/A
  • EYE N/A
  • EPS
  • ADPT N/A
  • EYE N/A
  • Revenue
  • ADPT $205,216,000.00
  • EYE $1,885,540,000.00
  • Revenue This Year
  • ADPT $32.76
  • EYE $8.92
  • Revenue Next Year
  • ADPT $15.81
  • EYE $3.32
  • P/E Ratio
  • ADPT N/A
  • EYE N/A
  • Revenue Growth
  • ADPT 21.60
  • EYE 5.08
  • 52 Week Low
  • ADPT $3.98
  • EYE $9.56
  • 52 Week High
  • ADPT $13.52
  • EYE $25.67
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 57.00
  • EYE 49.22
  • Support Level
  • ADPT $12.62
  • EYE $21.51
  • Resistance Level
  • ADPT $13.25
  • EYE $25.05
  • Average True Range (ATR)
  • ADPT 0.55
  • EYE 0.88
  • MACD
  • ADPT -0.05
  • EYE -0.08
  • Stochastic Oscillator
  • ADPT 58.13
  • EYE 55.65

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About EYE National Vision Holdings Inc.

National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.

Share on Social Networks: